AVO.L Share News (AVO)
AVO Share
AVO Share
AVO Share
AVO Share
AVO
AVO Share
AVO Broker
AVO Directors
AVO Financial
AVO
AVO Short
AVOFri, 30th Dec 2022 14:33
Advanced Oncotherapy PLC - London-based particle therapy for cancer treatment - Non-Executive Director Michael Bradfield buys 500,000 shares at 13.17 pence, worth GBP65,825, on Thursday. Now has 8.4 million shares, a 1.6% stake.
Current stock price: 13.84p, closed up 4.5% on Friday in London
12-month change: down 63%
By Tom Waite, Alliance News editor
Comments and questions to newsroom@alliancenews.com
Copyright 2022 Alliance News Ltd. All Rights Reserved.
(ShareCast News) - Cancer treatment developer Advanced Oncotherapy said it had made good full year progress in developing its 'LIGHT' system, although losses for the full year widened. The company's Geneva-based development team is working on a proprietary proton accelerator called Linac Image Guide
Read more(ShareCast News) - Advanced Oncotherapy has signed a £24m investment agreement with a fund advised by Metric Capital Partners LLP, pushing its shares up more than 7%. Metric Capital will invest the money in a financing facility to support Advanced Oncotherapy's provision of vendor financing for the
Read more(ShareCast News) - Advanced Oncotherapy was moving closer to success with its proton therapy for cancer treatment, updating the market on Tuesday of progress with its proton accelerator programme, dubbed 'LIGHT'. The AIM-traded company said its proton source, which was being constructed by Pantechni
Read more(ShareCast News) - Advanced Oncotherapy has reorganised its executive roles as it focuses on operational functions as well as ongoing sales and business development. The AIM-listed company said its executive chairman Michael Sinclair will have his role expanded to include chief executive officer, wh
Read more
